Market dynamics for generics must change amid ANDA pilot debut
The US Food and Drug Administration’s (FDA’s) pilot scheme to expedite the review of US-made generic medicines is welcomed but…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn
Danish pharma giant Novo Nordisk has inked a definitive deal with Omeros Corporation to acquire its late-stage-ready rare disease asset,…
-
Healthcare burden of neurological conditions “growing”, WHO warns
A new report from the World Health Organization (WHO) has highlighted the global healthcare burden of neurological disorders. In the…
-
Pfizer touts Tukysa in front-line breast cancer after Phase III victory
Pfizer’s Tukysa (tucatinib) has enhanced patient outcomes when used as a maintenance therapy during a late-stage trial in breast cancer.…
-
J&J spins off orthopaedics business against positive Q3 backdrop
Johnson & Johnson (J&J) has made the latest slimming down move across its company in recent years, saying it plans…
-
New US biotech hubs showing potential amid onshoring request
Ever since its early roots, the US has been a key player in the pharmaceutical industry, with prominent names like…
-
AstraZeneca inks Trump drug pricing deal amid tariff threats
UK-Swedish pharmaceutical giant AstraZeneca has signed a drug pricing deal with the US government, becoming the second industry titan to…
-
AstraZeneca sets $4.5bn Virginia API plant construction in motion
AstraZeneca has commenced construction of its $4.5bn active pharmaceutical ingredient (API) manufacturing facility in Virginia. The site, which is located…
-
Boehringer’s Jascayd nets first FDA IPF approval in over 10 years
Boehringer Ingelheim’s Jascayd (nerandomalist) has got the US Food and Drug Administration (FDA) nod in idiopathic pulmonary fibrosis (IPF), making…
-
Ex-FDA chief Peter Marks joins Eli Lilly’s infectious disease unit
Eli Lilly has tapped former US Food and Drug Administration (FDA) biologics lead, Peter Marks, as its new head of…